MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00277-022-05023-2

Медицинская библиотека · Annals of hematology · 2022

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.

Obr Ales, Benesova Katerina, Janikova Andrea, Mocikova Heidi, Belada David, Hruskova Andrea, Vockova Petra, Salek David, Sykorova Alice, Furst Tomas, Malarikova Diana, Papajik Tomas, Trneny Marek, Klener Pavel

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy. After a median follow-up of 14.0 months, 56 patients relapsed/progressed, and 45 died. The overall response rate was 66%, with 31% of complete metabolic remissions on PET/CT. The median progression-free and overall survival (OS) rates were 10.3 and 23.1 months, respectively. The median OS from ibrutinib failure was 3.7 months. High proliferation rate by Ki67 (≥ 30%) and two or more previous therapy lines both negatively correlated with outcome (HR = 2.2, p = 0.04, and HR = 2.06, p = 0.08, respectively). Female gender borderline correlated with better outcome (HR = 0.53, p = 0.08). In multivariate analysis, Ki67 and response to ibrutinib both correlated with OS (p < 0.05). Importantly, ibrutinib appeared to better control nodal and extranodal lymphoma than bone marrow (BM) involvement. From 20 patients with detectable BM infiltration (before ibrutinib initiation) achieving complete (n = 13) or partial (n = 7) metabolic remission, none achieved remission in BM. We confirmed good efficacy of ibrutinib in unselected heavily pre-treated MCL patients. Our findings support the use of a combination of ibrutinib and rituximab in patients with BM involvement.

Для цитирования: Obr Ales, Benesova Katerina, Janikova Andrea, Mocikova Heidi, Belada David, Hruskova Andrea, Vockova Petra, Salek David, Sykorova Alice, Furst Tomas, Malarikova Diana, Papajik Tomas, Trneny Marek, Klener Pavel. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.. Annals of hematology. 2022. DOI: 10.1007/s00277-022-05023-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.